Group One Trading
ACAD icon

Group One Trading’s Acadia Pharmaceuticals ACAD Stock Holding History

Group One Trading’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$125K Buy
5,600
+600
+12% +$14.3K ﹤0.01% 4529
2025
Q4 		$134K Sell
5,000
-63,700
-93% -$1.52M ﹤0.01% 4742
2025
Q3 		$1.47M Buy
68,700
+51,300
+295% +$1.21M ﹤0.01% 2631
2025
Q2 		$375K Buy
17,400
+9,300
+115% +$173K ﹤0.01% 3713
2025
Q1 		$135K Sell
8,100
-40,900
-83% -$743K ﹤0.01% 4361
2024
Q4 		$899K Sell
49,000
-8,400
-15% -$136K ﹤0.01% 2662
2024
Q3 		$883K Buy
57,400
+13,300
+30% +$222K ﹤0.01% 2408
2024
Q2 		$717K Sell
44,100
-26,900
-38% -$434K ﹤0.01% 2266
2024
Q1 		$1.31M Sell
71,000
-113,800
-62% -$2.82M 0.01% 1841
2023
Q4 		$5.79M Sell
184,800
-338,800
-65% -$8.09M 0.02% 1030
2023
Q3 		$10.9M Buy
523,600
+471,300
+901% +$12.8M 0.04% 480
2023
Q2 		$1.25M Buy
52,300
+36,500
+231% +$811K ﹤0.01% 2148
2023
Q1 		$297K Buy
15,800
+8,000
+103% +$152K ﹤0.01% 3290
2022
Q4 		$124K Sell
7,800
-9,800
-56% -$153K ﹤0.01% 4247
2022
Q3 		$288K Sell
17,600
-76,500
-81% -$1.24M ﹤0.01% 3779
2022
Q2 		$1.33M Buy
94,100
+74,700
+385% +$1.39M ﹤0.01% 2462
2022
Q1 		$470K Sell
19,400
-4,800
-20% -$116K ﹤0.01% 3878
2021
Q4 		$565K Buy
24,200
+2,700
+13% +$54.3K ﹤0.01% 3988
2021
Q3 		$357K Sell
21,500
-12,400
-37% -$239K ﹤0.01% 4564
2021
Q2 		$827K Sell
33,900
-243,500
-88% -$5.5M ﹤0.01% 3625
2021
Q1 		$7.16M Sell
277,400
-26,100
-9% -$1.15M 0.01% 1210
2020
Q4 		$16.2M Sell
303,500
-900
-0.3% -$44.7K 0.03% 546
2020
Q3 		$12.6M Buy
304,400
+18,200
+6% +$786K 0.04% 430
2020
Q2 		$13.9M Buy
286,200
+5,000
+2% +$240K 0.06% 338
2020
Q1 		$11.9M Sell
281,200
-141,000
-33% -$5.81M 0.1% 202
2019
Q4 		$18.1M Buy
422,200
+159,500
+61% +$6.94M 0.12% 171
2019
Q3 		$9.46M Sell
262,700
-539,900
-67% -$16.4M 0.08% 298
2019
Q2 		$21.5M Buy
802,600
+728,300
+980% +$18.6M 0.19% 80
2019
Q1 		$2M Buy
74,300
+12,300
+20% +$287K 0.02% 938
2018
Q4 		$1M Sell
62,000
-61,800
-50% -$1.2M 0.01% 1508
2018
Q3 		$2.57M Buy
123,800
+11,600
+10% +$183K 0.02% 982
2018
Q2 		$1.71M Sell
112,200
-84,300
-43% -$1.5M 0.01% 1259
2018
Q1 		$4.42M Sell
196,500
-55,900
-22% -$1.55M 0.04% 530
2017
Q4 		$7.6M Buy
252,400
+56,500
+29% +$1.81M 0.05% 430
2017
Q3 		$7.38M Sell
195,900
-33,300
-15% -$1.08M 0.07% 359
2017
Q2 		$6.39M Buy
229,200
+14,200
+7% +$423K 0.07% 359
2017
Q1 		$7.39M Sell
215,000
-173,700
-45% -$6.13M 0.09% 270
2016
Q4 		$11.2M Buy
+388,700
New +$10.3M 0.11% 188
2013
Q3 		– Sell
-700,200
Closed -$12.7M – 5102
2013
Q2 		$12.7M Buy
+700,200
New +$9.64M 0.31% 45

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Group One Trading's ACAD Position: Q1 2026 in Review

Group One Trading reduced its Acadia Pharmaceuticals (ACAD) stake by 67% in Q1 2026, selling an estimated $150K and leaving 3,032 shares worth $67.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5045.

Group One Trading first reported a position in ACAD in Q2 2013 and has held it in 40 quarters since. The position peaked at $13.9M in Q1 2014. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Group One Trading held 3,032 shares of Acadia Pharmaceuticals worth $67.5K as of Q1 2026.
  • Group One Trading sold 6,281 Acadia Pharmaceuticals shares in Q1 2026, an estimated $150K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5045 holding.
  • Group One Trading first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
  • Group One Trading's Acadia Pharmaceuticals position peaked at $13.9M in Q1 2014.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.